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Gliomas are a complex and heterogeneous group of primary brain
tumours. Mortality due to brain tumour has risen from 0.5% of
cancer mortality in 1950 to almost 2.0% in 1985. The low incidence
of this disease has limited the amount of data available,
particularly for treatment.
OBJECTIVES
The objective is to define guidelines for the management of adult
patients with glioma. The management of spinal, non-glial,
hypophyseal, neuronal tumours and schwannomas and the
management of childhood glioma are not covered in this
document.
METHODS
The general methodology used has already been described (Fervers
et al, 2001). For this specific SOR, a multidisciplinary working
group was set up by the French National Federation of Cancer
Centres (Fe ´de ´ration Nationale des Centres de Lutte Contre le
Cancer–FNCLCC) and the Association of French-speaking Neuro-
oncologists (Association des Neuro-Oncologues d’Expression
Franc¸aise–ANOCEF) to review the best available evidence on the
management of adult patients with glioma.
Medline
s and Cancerlit
s were searched using a specific
strategy, for the period 1990–2000. In addition, the members of
the working group provided references from their personal sources
up to 2001. The majority of the articles thus identified were in
English or French. Many of the articles identified reported results
for heterogeneous populations of patients (adults and children,
and types of glioma), and therefore, when possible, information
had to be extracted for specific populations and tumours.
However, as this was not possible in all publications, not all the
available literature could be analysed.
Following the selection and critical appraisal of the articles, the
working group produced a document with the proposed ‘Stan-
dards’, ‘Options’ and ‘Recommendations’ (SORs) for the manage-
ment of adult patients with glioma, based on scientific evidence or
expert agreement. The document was then peer-reviewed by
independent experts, and their comments were integrated in the
final version. When all the members of the working group agree,
based on the best available evidence, that a procedure or
intervention is beneficial, inappropriate, or harmful, it is classified
as a ‘Standard’, and when the majority agree, it is classified as an
‘Option’ (Table 1). In the SORs, there can be several ‘Options’ for a
given clinical situation. ‘Recommendations’ provide additional
information that enable the available options to be ranked using
explicit criteria (e.g. survival, toxicity) with an indication of the
level of evidence. These recommendations thus help clinicians to
select an appropriate option. Thus, clinicians can make choices for
the management of patients using this information and taking into
consideration local circumstances, skills, equipment, resources
and/or patient preferences. The adaptation of the SOR to the local
situation is allowable if the reason for the choice is sufficiently
transparent and this is crucial for successful implementation.
Inclusion of patients in clinical trials is an appropriate
form of patient management in oncology and is recommended
frequently within the SORs, particularly in situations where
only weak evidence exists to support a procedure or an
intervention.
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reviewed, but also on the concordance of the results (Table 2).
When no clear scientific evidence exists, judgement is made
according to the professional experience and consensus of the
expert group (‘expert agreement’
1), and this is validated by the
peer-review process.
This summary version has been translated from the French
summary version, which was based on the integral version that will
be published on the internet (http://www.fnclcc.fr).
INCIDENCE AND RISK FACTORS FOR
INTRACRANIAL GLIOMA
An increased incidence of intracranial glioma has been reported
(level of evidence: C). With the exception of phacomatosis, familial
predisposition to these tumours has been reported in fewer than
5% of patients, and extensive family screening is therefore not
warranted.
Exposure to nitrate derivatives has been identified as a risk
factor, and this constitutes occupational illness (level of evidence:
C). No clear relationship between exposure to mobile telephones
and increased risk of brain tumours has been documented (level of
evidence: C). Exposure to low-frequency electromagnetic fields is
thought to be associated with an increased risk (level of evidence:
C). A national register of primary brain tumours should be created
(recommendation).
DIAGNOSIS: HISTOLOGY, MOLECULAR BIOLOGY
AND CYTOGENETICS
To avoid misclassification (generally lower grade), the surgeon
should ensure that the samples are representative of the lesion,
particularly of any area of contrast enhancement present
(standard). The quality of the sample should be sufficient to allow
histological diagnosis, that is, type of glioma and grade (standard),
and also molecular-biological and cytogenetic investigations
(option).
Sample processing
Some techniques require specific processing, therefore the sample
taken by the surgeon should be processed immediately by the
pathologist (recommendation). For histological diagnosis, the
sample should be fixed with a 10% formaldehyde or zinc
formaldehyde solution before embedding in paraffin (standard).
Alcohol–formaldehyde–acetic acid (AFA) can be used for fixation
(option) and is recommended for some molecular-biological
investigations. Smear samples can be prepared from fresh tissue
for diagnosis (recommendation). If the tissue is to be used
for research purposes, a smear sample can be used to confirm
tumour involvement of the processed tissue. For electronic
microscopy, fixation with a 2% glutaraldehyde solution is possible
(option).
Sterile cell culture can be used for cytogenetic investigations
(option). The sample can be immediately frozen in liquid nitrogen
for molecular–biological investigations and for inclusion in a
tumour tissue bank (option).
Histological diagnosis
The 2000 World Health Organization (WHO) classification is the
standard for diagnosis and histoprognostic grading of glioma.
Other classification systems (e.g. Smith, Daumas–Duport) can be
used to complement the type and grading of oligodendroglioma
(option).
Diagnostic or prognostic immunohistochemistry (GFAP, Ki67,
etc.) can be performed (option). A search for deletions of 1p and
19q chromosome should be undertaken, particularly in patients
with oligodendroglial tumours (recommendation). Comparison of
the results from histology and imaging can help to establish the
diagnosis (option). Review of the histology by an expert committee
is recommended in all difficult samples and in all clinical trials
(recommendation).
Table 1 Definition of ‘Standards, options and recommendations’
Standards Procedures or treatments that are considered to be of benefit, inappropriate or harmful by unanimous decision, based on the
best available evidence
Options Procedures or treatments that are considered to be of benefit, inappropriate of harmful by a majority, based on the
best available evidence
Recommendations Additional information to enable the available options to be ranked using explicit criteria (e.g., survival, toxicity)
with an indication of the level of evidence
Table 2 Definition of level of evidence
Level A
There exists high standard meta-analysis or several high-standard randomised clinical trials that give consistent results
Level B
There exist good quality evidence from randomised trials (B1) or prospective or retrospective studies (B2). The results are consistent when considered together
Level C
The methodology of the available studies is weak or their results are not consistent when considered together
Level D
Either the scientific data do not exist or there is only a series of cases
Expert agreement
The data do not exist for the method concerned, but the experts are unanimous in their judgement
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Diagnosis
Preoperative imaging should be performed with and without
intravenous contrast medium (standard). MRI should be used in
preference to CT scanning (standard, expert agreement). Three-
dimensional scans should be taken using the same technique
(standard). T1-weighted (with and without contrast medium), T2-
weighted MR images and/or fluid-attenuated inversion recovery
(FLAIR) imaging should be undertaken (standard). MR images
should be converted into a digital format on a numerical support
system (e.g. CD) for possible subsequent dosimetric studies
(recommendation).
This imaging can be combined with functional MR, MR
diffusion imaging, MR perfusion studies and/or with proton MR
spectroscopy (options).
In the setting of clinical trials, it is possible to perform a
positron emission tomography (PET) scan or a single photon
emission computed tomography (SPECT) scan (options).
Post-therapeutic and follow-up imaging
After surgical removal, imaging can be used to assess any residual
tumour (option). MRI should be used, if possible (recommenda-
tion, level of evidence: B2), within 72h, with and without contrast
medium (recommendation). MRI is preferable to CT-scanning for
follow-up of disease progression (recommendation).
TREATMENT MODALITIES
Surgery
Histological confirmation Histological confirmation of the diag-
nosis should be obtained, because neuroradiological investigations
are not sufficiently specific (standard, expert agreement). In
exceptional situations, for example, elderly patients with a deep-
seated lesion, presenting a very poor systemic or neurological
condition, the clinician may consider that the risk from biopsy
outweighs the risk from misdiagnosis and decide not to perform
biopsy (option, expert agreement). However, this should remain
exceptional.
Surgery Criteria for surgery include the patient’s age, general
health performance status, as well as investigations (anatomical/
functional data, presumed tumour type) and the technical support
for surgery available (expert agreement).
Tumour resection should be optimal, that is with margins as
wide as possible, avoiding any major functional risks (standard,
expert agreement).
Surgical excision is the best means to obtain tissue samples that
are representative of the whole lesion and to reduce the mass
effect, if present (standard).
The use of technical aids (preoperative functional MR, ultra-
sound aspiration, surgical microscope, neuro-navigation, intrao-
perative brain mapping) can optimise surgical resection (option,
expert agreement).
A biopsy (stereotactic, open skull) can be performed when
surgical excision is not planned (standard).
Radiotherapy
External-beam radiotherapy Irradiation should be targeted using
conventional external-beam radiotherapy (standard, level of
evidence: B1). The gross tumour volume, or GTV, corresponds
to contrast-enhanced image or, after complete excision, to the
edges of the operative cavity (standard, expert agreement). For
heterogeneous tumours (with hypo-intense and hyper-intense
regions), and for hypo-intense tumours on T1-weighted images,
the hypo-intense tumour volume is included in the GTV
(recommendation, expert agreement).
The clinical tumour volume, or CTV, should include a safety
margin of 20mm outside the GTV limit in all three dimensions
(standard, expert agreement). This safety margin can be reduced,
depending on the grade, histological type and the tumour volume,
(option, expert agreement). Noncoplanar focalised multiple beam
(3–5) should be used to minimise the total fractionated dose
delivered to the non-diseased brain (standard). Dose–volume
histograms can be useful for defining the best treatment plan
(option).
All fields should be irradiated the same day with a fractionated
dose varying from 1.8 to 2Gy per fraction and per day, five times
per week (standard). The dose should be adapted according to the
histological type and the grade of the lesion and should not exceed
a total of 60Gy (standard).
Prophylactic corticosteroid treatment should not be prescribed
routinely (option, expert agreement), but can be used to reduce the
risk of acute or early–delayed encephalopathy (radiation-induced
oedema).
Complications following external-beam radiotherapy Clinical
and/or radiological deterioration in the 2 months after the end
of radiotherapy should be interpreted with caution and not
automatically be considered as a treatment failure (standard, level
of evidence: C). The irradiation protocol (volume, total dose and
particularly the dose per fraction), the presence of risk factors such
as age (over 50 years old) and/or previous vascular disease
(hypertension, diabetes, hyperlipidaemia) are associated with an
increased risk for late neurological complications (radionecrosis,
radiation-induced leucoencephalopathy) (level of evidence: C).
The results from FDG-PET scanning, proton MR spectroscopy
or
99mTc methoxy isobutyl isonitrile (MIBI) brain scintigraphy can
help the differential diagnosis between recurrence and radio-
necrosis (option).
Other irradiation modalities Brachytherapy (level of evidence:
B2), stereotactic radiotherapy (expert agreement), use of radio-
potentiation (level of evidence: B1) and heavy particles (expert
agreement) should only be used in the setting of clinical trials since
their efficacy has not been proved (recommendation).
Chemotherapy
Efficacy of systemic chemotherapy The efficacy of the following
nitrosourea derivatives has been reported: 1,3-bis(2-chloroethyl)-
1- (BCNU) (level of evidence: A); 1-(2-chloroethyl)-3-cyclohexyl-1-
nitrosourea (CCNU) (level of evidence: C) and fotemustine (level
of evidence: C). Nitrosourea molecules, particularly carmustine,
have only been evaluated in clinical trials using definitions of
response that are no longer used.
Nitrosourea derivatives can be used in the PCV combination:
procarbazine, CCNU and vincristine (option, level of evidence:
B2).
For second-line treatment, temozolomide (level of evidence:
variable depending on the histology of the tumour), platinum
derivatives either as a mono- or poly-chemotherapy (level of
evidence: C) or procarbazine (expert agreement) can be consid-
ered. It is also possible to use another nitrosourea, if the time
between the first- and second-line treatment is sufficiently long
(level of evidence: D).
Efficacy of local chemotherapy A local implant of BCNU
can be considered in patients with recurrent disease (option,
level of evidence: C). Other regional drug delivery strategies should
only be envisaged in the setting of clinical trials (recommenda-
tion).
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Pharmacological agents with specific modes of action (e.g. protein
kinase C inhibitors) targeting with monoclonal antibodies or
ligands, immunotherapy and/or gene therapy should only be used
in the setting of clinical trials (recommendation).
Concomitant medical treatments
Treatment of oedema Patients with clinical or radiological
evidence of brain oedema should be treated (standard, expert
agreement). The minimal effective dose should be determined and
regularly re-evaluated (standard, expert agreement).
Treatment with corticosteroid or, less frequently, an osmotic
agent can be considered (option, expert agreement). Patients
should be monitored for side effects (standard, expert agreement).
Methylprednisolone and prednisolone should be prescribed if
possible, as single daily doses, in the morning (recommendation,
expert agreement). If lymphoma is suspected, corticosteroid
therapy should be avoided prior to obtaining histological
confirmation, except for those patients whose neurological status
requires this therapy (standard, expert agreement).
The clinical and radiological evaluation of the tumour evolution
should take into account the variations in the dose of corticoster-
oid (standard, expert agreement).
Preventive treatment for gastrointestinal complications Perio-
perative H2-receptor blockers or proton pump inhibitors can be
used to prevent gastrointestinal complications in patients receiving
high doses of corticosteroids and/or in those with risk factors for
ulcers (e.g. previous ulcers, concomitant anticoagulant or NSAID)
(recommendation).
Treatment of epilepsy
Peri-operative treatment: Treatment for epilepsy can be pre-
scribed routinely during the perioperative period for patients who
have had seizures (standard). In other patient, peri-operative
anticonvulsant treatment is an option (option, level of evidence: C).
Post-operative treatment: In patients with previous seizures,
anticonvulsant treatment should be continued in the postoperative
period (standard). Since the efficacy of antiepileptic treatment in
patients who have not had seizures has not been demonstrated, its
prescription should be tailored to each patient (option, expert
agreement).
There are no data to guide the choice of which drug(s) should be
used for antiepileptic treatment (recommendation). Any inducing
and/or potentiating effect on the toxic effects of the chemotherapy
should be taken into consideration (recommendation, expert
agreement). First-line treatment should be single-drug treatment
(recommendation).
Analgesic treatment Appropriate analgesic treatment should be
prescribed when necessary: for example, for intracranial hyperten-
sion, neoplastic meningitis, pain associated with retractions due to
permanent deficit (standard).
Anticoagulant treatment Surveillance, prevention and treatment
for thromboembolism should be performed, since this occurs
frequently in patients with glioma (standard). Prophylactic use of
low-molecular weight heparin and compression stockings is
recommended for preventing perioperative thromboembolic
complications (recommendation, level of evidence: B2). After 4–
5-days of surgery, in the event of a thromboembolic complication,
anticoagulant treatment at a therapeutic dose can be prescribed,
without undue haemorrhagic risk (recommendation, expert
agreement).
SPECIFIC TREATMENT STRATEGIES
The management of patients with suspected glioma should be
discussed with a multidisciplinary neuro-oncology team (stan-
dard).
Grade 3 and 4 glioma
Prognostic factors Age and preoperative functional status, as well
as histological type and grade of the tumour are recognised
prognostic factors (level of evidence: A).
In patients with oligodendroglioma, deletion of chromosome 1p
(particularly when there is also a deletion of chromosome 19q) is a
favourable prognostic factor for survival and probably for
treatment response (level of evidence: B2).
Diagnosis and initial treatment For biopsy or surgery, all
patients should be routinely transferred to a specialist centre
(standard).
All patients, except those with a high physiological age, and/or
those with co-morbidities and/or with a poor performance status,
and/or with lesions in functional, multifocal or centrally localised
zones, should be offered optimal surgical resection when
technically feasible, and if there is a low risk of permanent
postoperative functional deterioration (standard, expert agree-
ment). If this is not possible, histological evidence should be
obtained by biopsy (standard).
Investigations to assess residual tumour after surgical resection
can be undertaken (see section on Post-therapeutic and follow-up
imaging), but their prognostic value, in terms of survival, is
controversial (option, expert agreement).
Optimal cancer treatment plans are not feasible in only a low
percentage of patients (high physiological age, multiple patholo-
gies, poor functional status, centrally localised lesion, etc.) and in
this rare situation biopsy is not mandatory (option). In this
situation, palliative treatment, radiotherapy or chemotherapy can
be offered, tailored to the individual patient (options) (Figure 1).
Postoperative treatment (Figure 2) All histology and findings
from imaging and clinical examinations should be taken into
account before initiating any additional anticancer treatment to
verify the coherence of the clinical picture (recommendation).
Additional treatment should be started within a month (recom-
mendation). The modalities of radiotherapy and chemotherapy
should be adapted to the patient’s status.
Patients should be included in clinical trials to evaluate
postoperative treatment for high-grade glial tumours (recommen-
dation).
First-line external-beam radiotherapy should be offered to
patients with high-grade glioma since it has been shown to
improve survival (standard, level of evidence: A) although these
clinical trials excluded patients with poor prognostic factors, such
as a low Karnofsky score and/or advanced physiological age and/or
large or multifocal tumours. A total dose of 60Gy should be
delivered, with a fractionation from 1.8 to 2Gy per fraction and per
day (recommendation).
Glioblastoma and anaplastic astrocytoma: Radiotherapy should
be offered (standard, level of evidence: A). This can be combined
with chemotherapy with a nitrosourea-based chemotherapy
(option, level of evidence: B1).
When chemotherapy is selected, mono-drug chemotherapy with
a nitrosourea should be offered to patients with glioblastoma
(standard, level of evidence: A) and either mono-drug chemother-
apy with a nitrosourea (BCNU), or multidrug chemotherapy with
procarbazine, lomustine, and vincristine (PCV) for patients with
anaplastic astrocytoma (recommendation, level of evidence: C).
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apy should be proposed for patients with anaplastic oligoden-
droglioma and oligoastrocytoma (standard, level of evidence: B2).
Chemotherapy (PCV) has been shown to be efficacious in patients
with oligodendroglioma. A combination of radiotherapy and
chemotherapy can be considered, although the optimal timing of
chemotherapy (neoadjuvant treatment vs adjuvant treatment vs
treatment when the tumour recurs) has not been defined (option,
level of evidence: B2). In selected patients with large unresectable
tumours, and/or those who are elderly, and/or those who have had
a complete response to neoadjuvant chemotherapy, it is not
necessary to administer radiotherapy routinely (option, expert
agreement).
Treatment of tumour recurrence (Figure 3) Patients should be
included in clinical trials to evaluate treatment of tumour
recurrence (recommendation).
Five therapeutic options can be considered (options, expert
agreement): surgery, systemic chemotherapy, local chemotherapy,
second-line radiotherapy or palliative care without specific antic-
ancer treatment. The decision to perform surgery should only be
taken after multidisciplinary consultation (recommendation). For
selected patients, newer irradiation techniques can be considered,
using different modalities (brachytherapy, stereotactic radiother-
apy) (option).
Glioblastoma: There is no standard. Five therapeutic options can
be considered (options, expert agreement): surgery, systemic
chemotherapy, local chemotherapy, second-line radiotherapy or
palliative care without specific anticancer treatment. The following
drugs have shown moderate efficacy, and can be used if
chemotherapy is indicated: temozolomide (option, level of
evidence: C), nitrosourea molecules (option) and carmustine
implants (option, level of evidence: C).
Anaplastic astrocytoma: There is no standard. Five therapeutic
options can be envisaged (options, expert agreement): surgery,
systemic chemotherapy, local chemotherapy, second-line radio-
therapy or palliative care without specific anticancer treatment.
Temozolomide, which has been shown to have significant efficacy
(option, level of evidence: C), and carmustine implants, which have
been shown to have moderate efficacy, can be administered if
chemotherapy is indicated (option, level of evidence: C).
Nitrosourea molecules can be proposed, if the patient has not
received them previously (option, expert opinion).
Anaplastic oligodendroglioma and oligoastrocytoma: The sec-
ond-line strategy depends on the first-line treatment used:
 In patients with recurrence after radiotherapy alone: che-
motherapy with PCV can be considered (option, level of
evidence: B2);
Grade 3−4 glioma
Optimal cancer
treatment possible?
Initial treatment
Yes No
Patients with
- a high physiological age
- multiple pathologies,
- poor functional status,
- multifocal lesions or lesions in
functional or centrally localised
regions Standards:
   transfer to a specialised centre for surgery 
   or biopsy
   evaluation of operability criteria
   optimal resection
except for patients:
- with high physiological age
- and/or with several co-morbidities
- and/or with a poor performance status
- and/or with multifocal lesions or lesions in
functional or centrally localised regions
biopsy if optimal resection is not possible
Option :
   investigation for the presence of residual tumour
Standard:
there is no standard
Options:
   transfer to a specialised centre for expert
   evaluation
   no biopsy
   no surgery
   palliative treatment
   radiotherapy
   chemotherapy
Postoperative 
treatment
Figure 2

after surgical resection
Figure 1 Supratentorial grade 3–4 glioma–initial management.
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Confirmed histology
Complementary postoperative treatment
Malignant glioblastoma Anaplastic astrocytomas Oligodendrogliomas and
anaplastic oligoastrocytomas
Standard:
   radiotherapy
Option:
   mono-drug chemotherapy 
   with a nitrosourea
Standard:
   radiotherapy
Options:
   mono-drug chemotherapy 
   with a nitrosourea
 - chemotherapy with PCV
Standard:
   radiotherapy
Options:
   radiotherapy followed by
   chemotherapy (PCV)
   chemotherapy (PCV) followed 
   by radiotherapy
   chemotherapy alone (PCV)
   - for patients with large tumours
   - and/or those who are elderly
   - and/or those who had a 
   complete response to
   chemotherapy
Figure 2 Supratentorial grade 3–4 glioma–postoperative treatment.
Grade 3−4 glioma − tumour recurrence
Options:
   surgery
   systemic chemotherapy
   local carmustine implants
   palliative care without specific anticancer treatment
Glioblastoma Anaplastic
astrocytomas
Oligodendrogliomas and
anaplastic oligoastrocytomas
Options:
   temozolomide
   nitrosourea if not
   used previously
   local carmustine
   implants
If chemotherapy is
selected:
Options:
   temozolomide
   nitrosourea if not
   used previously
   local carmustine
   implants
If chemotherapy is
selected:
Initial treatment with
radiotherapy:
Option:
  chemotherapy (PCV)
Initial treatment with
radiotherapy and
chemotherapy (PCV)
Initial treatment with
chemotherapy (PCV):
Option:
   temozolomide
Options:
   radiotherapy alone
   second line chemothe-
   rapy
For certain patients radiotherapy can be
Standard: there is no standard
re-administered
Figure 3 Supratentorial grade 3–4 glioma–treatment for tumour recurrence.
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apy with PCV: chemotherapy with temozolomide can be
considered (option, level of evidence: C);
 In patients with recurrence after chemotherapy alone: radio-
therapy should be considered when possible (option). If
radiotherapy is not possible (older patients in poor condition
with extensive tumour), second-line chemotherapy (option) can
be considered.
Grade 2 glioma (Figure 4)
The therapeutic decision must weigh the benefit of providing relief
for distressing symptoms and avoiding or delaying anaplastic
transformation, against the iatrogenic risk from treatment,
particularly in patients whose tumour may fail to progress for a
long time.
Prognostic factors The factors for poor prognosis in patients with
grade 2 glioma are:
 age X35–40 years (level of evidence: B1),
 low Karnofsky score (level of evidence : B1),
 intracranial hypertension, functional deficit (level of evidence:
C),
 uncontrolled epilepsy (level of evidence: C),
 large or rapidly increasing tumour volume and mass effect (level
of evidence: C),
 localisation in a functional zone (level of evidence: C),
 involvement of deep structures (level of evidence: C),
 contrast enhancement on MR images (level of evidence: C).
Diagnosis and initial treatment Radiological evaluation of grade
2 glioma should be based on MRI, both for diagnosis and follow-
up (standard).
For patients with a grade 2 glioma, optimal resection involves a
total or subtotal removal of the tumour volume defined in T2 and/
or the FLAIR sequence on MRI (expert agreement).
The prognostic value of complete resection is uncertain, but
when it is possible to aim for radiologically complete resection
safely, surgery should be undertaken (standard, expert agreement).
When radiotherapy is proposed, the dose should be between 45
and 54Gy (standard, level of evidence: B2). It is recommended to
use a dose between 50 and 54Gy (recommendation, expert
agreement). Chemotherapy can be proposed, in symptomatic
oligodendroglial tumours, preferentially in clinical trials, since its
role in this indication is uncertain (option, level of evidence: D).
The therapeutic strategy is based on the operability of the
tumour and prognostic factors.
If optimal resection is possible:
 In the presence of at least one poor prognostic factor, surgical
resection should be undertaken (standard).
 In the absence of poor prognostic factors, surgical resection or
surveillance with or without biopsy can be considered (options).
If optimal resection is not possible:
 In the presence of at least one poor prognostic factor, partial
resection, partial resection followed by radiotherapy, radio-
therapy alone and chemotherapy can be proposed (options).
The last two options should only be considered after histological
confirmation.
Grade 2 glioma
Standard
   seek expert opinion
   pathological diagnosis before treatment
Prognostic factors
   age > 35−40 years
   uncontrolled epilepsy
   deficit symptoms or intracranial
   hypertension
   large size, mass effect
   rapidly increasing volume
   contrast enhancement
   low Karnofsky score
   localisation in functional zone
   involvement of deep structure
No Optimal resection
possible?
Yes No Presence of at least
one factor
Yes No Presence of at least
one factor
Standard:
   surgical resection
Standard:
   surgical resection
   radio-clinical follow-
   up with or without 
   biopsy
Standard:
there is no standard
Options:
   partial surgery
   partial surgery followed 
   by radiotherapy
   radiotherapy alone after
   histological confirmation
   chemotherapy if
   symptomatic, after
   histological confirmation
   radio-clinical follow-up
   with or without biopsy
   partial surgery
   partial surgery followed
   by radiotherapy
Yes
there is no standard
Options:
Options:
Standard:
there is no standard
Figure 4 Grade 2 glioma.
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without biopsy, partial resection, partial resection followed by
radiotherapy or biopsy followed by radiotherapy can be
considered (options).
Patients should be included in clinical trials to evaluate
therapeutic strategies (recommendation).
Gliomatosis cerebri
The diagnosis of gliomatosis cerebri should be based on a
comparison of the biopsy and radiological results (standard,
expert agreement).
Three treatment options can be considered: chemotherapy alone
(option, level of evidence: D); follow-up for asymptomatic patients,
without radiological signs of progression (option); and whole-
brain radiotherapy (option).
Pilocytic astrocytoma, subependymoma and
xanthoastrocytoma
Pilocytic astrocytoma (Figure 5) Pilocytic astrocytoma should no
longer be called low-grade astrocytoma or glioma. The growth of
pilocytic astrocytoma is slow, and sometimes absent, particularly
for neurofibromatosis type 1.
Complete surgical resection significantly improves survival and
often cures these patients (level of evidence: C). Optimal surgical
resection should be offered to patients satisfying the operability
criteria (standard). Even if complete resection is not possible,
surgery can be considered, if the operability criteria are satisfied
(option).
Postoperative evaluation of the quality of the surgical resection
should be performed with MRI (standard, expert agreement). If the
MRI confirms complete resection, simple clinical follow-up is
indicated (option, expert agreement). If the resection is incom-
plete, annual follow-up, over many years (clinical and MRI),
should be undertaken (option, expert agreement).
When resection is incomplete or not possible, and there is
progression of the tumour, radiotherapy and/or chemotherapy can
be considered although the indications and optimal modalities are
uncertain (option).
Pleomorphic xanthoastrocytoma (Figure 6) Optimal surgical
resection should be undertaken in all patients (standard, level of
evidence: C).
If the histological examination reveals anaplastic change (grade
3), postoperative external-beam radiotherapy should be under-
taken, irrespective of the quality of the surgical excision (standard,
level of evidence: C).
If clinical or radiological tumour progression is observed,
surgery and/or external-beam radiotherapy can be considered
(option, level of evidence: C).
Clinical follow-up should include MRI (recommendation).
A pleomorphic xanthoastrocytoma register should be estab-
lished (recommendation).
Subependymoma (Figure 7)
First-line treatment for a symptomatic subependymoma is optimal
resection (standard). In patients with recurrence, further optimal
resection or radiotherapy can be considered (option).
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Figure 5 Pilocytic astrocytoma.
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Figure 6 Pleomorphic xanthoastrocytoma.
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The histological grade can be taken into consideration, but it has
an uncertain prognostic value (option). The work-up can include a
spinal MRI and a lumbar puncture in patients with infratentorial
tumours (option).
Localised lesions Surgery is the standard treatment (standard,
level of evidence: B) and complete surgical resection confirmed by
early postoperative MRI is a good prognostic factor (level of
evidence: B2). If radiotherapy is administered, localised radio-
therapy, not craniospinal radiotherapy, should be proposed
(standard, expert agreement).
In patients with complete resection and a grade 2 tumour, no
complementary treatment is necessary (standard). For patients
with a grade 3 tumour, focalised postoperative radiotherapy
(option, level of evidence: C) or follow-up (option) can be offered.
In patients with incomplete resection and a grade 2 tumour, the
treatment options are: follow-up, further resection or localised
postoperative radiotherapy (options, level of evidence: C). If the
tumour is grade 3, localised radiotherapy should be offered
(standard). In this case, further resection or chemotherapy can be
considered (options).
In patients with recurrence, further resection, radiotherapy,
chemotherapy or palliative treatment can be considered (options).
Metastatic lesions Patients with metastatic disease at presenta-
tion have a poor prognosis (level of evidence: B2).
Craniospinal radiotherapy should be offered (standard, expert
agreement). Optimal surgical resection can be undertaken before
radiotherapy (option). Chemotherapy can be offered (option).
Brain stem glioma (Figure 9)
In patients with hydrocephalus, a cerebrospinal fluid shunt should
be offered (standard). Lesions with different prognoses can be
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Figure 8 Intracranial ependymoma.
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appearance.
Diffuse lesions Biopsy can be considered (option). The patient’s
clinical status should be considered in any treatment decision
(recommendation):
 Only progressive tumours, as diagnosed from clinical symptoms
and/or radiological images, should be treated with radiotherapy
(option, level of evidence: C).
 Chemotherapy can be considered after failure of radiotherapy
(option).
 For certain patients, palliative treatment only can be considered
(option).
Focal exophytic lesions Biopsy or resection can be considered
(option). Depending on the histology (if this can be determined:
see section on each histological type), age and MRI results, optimal
resection, radiotherapy or follow-up alone can be considered
(options). An optimal resection should be undertaken whenever
possible (recommendation).
Tectal plate lesions No treatment, with follow-up alone, can be
considered (option).
Neurofibromatosis type 1 Follow-up alone can be considered for
patients with non-progressive brain stem glioma (option). Radio-
therapy and/or chemotherapy can be considered for patients with
progressive brain stem glioma (option).
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Figure 9 Brain stem glioma.
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